High Growth Tech Stocks To Watch In Hong Kong This September 2024

As global markets face a downturn, with the S&P 500 experiencing its worst weekly drop in 18 months and Hong Kong's Hang Seng Index also retreating, investors are increasingly cautious about economic slowdowns and market volatility. In this climate, identifying high-growth tech stocks in Hong Kong requires a keen eye for companies with strong fundamentals, innovative capabilities, and resilience to broader market pressures.

Top 10 High Growth Tech Companies In Hong Kong

Name	Revenue Growth	Earnings Growth	Growth Rating
Wasion Holdings	22.37%	25.47%	★★★★★☆
MedSci Healthcare Holdings	48.74%	48.78%	★★★★★☆
Inspur Digital Enterprise Technology	25.37%	39.10%	★★★★★☆
Cowell e Holdings	31.82%	35.43%	★★★★★★
RemeGen	26.30%	52.19%	★★★★★☆
Akeso	32.86%	54.67%	★★★★★★
Innovent Biologics	21.45%	59.82%	★★★★★☆
Sichuan Kelun-Biotech Biopharmaceutical	24.70%	8.53%	★★★★★☆
Biocytogen Pharmaceuticals (Beijing)	21.53%	109.17%	★★★★★☆
Beijing Airdoc Technology	37.47%	93.35%	★★★★★☆

Click here to see the full list of 45 stocks from our SEHK High Growth Tech and AI Stocks screener.

We'll examine a selection from our screener results.

Innovent Biologics (SEHK:1801)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Innovent Biologics, Inc. is a biopharmaceutical company that develops and commercializes monoclonal antibodies and other drug assets for oncology, ophthalmology, autoimmune, cardiovascular, and metabolic diseases in China with a market cap of HK$68.84 billion.

Operations: Innovent Biologics generates revenue primarily from its biotechnology segment, which amounted to CN¥7.46 billion. The company focuses on developing and commercializing monoclonal antibodies and other drug assets across various therapeutic areas in China.

Innovent Biologics has shown impressive growth, with earnings forecasted to increase by 59.82% annually and revenue expected to rise by 21.4% per year, outpacing the Hong Kong market's 7.3%. Despite a net loss of CNY 392.62 million for H1 2024, the company's R&D expenses reflect its commitment to innovation; investing heavily in developing breakthrough treatments like Dupert® for NSCLC and IBI3016 for hypertension. This strategic focus on high-impact therapies positions Innovent well within the competitive biotech landscape in Hong Kong.

• Delve into the full analysis health report here for a deeper understanding of Innovent Biologics.

• Gain insights into Innovent Biologics' past trends and performance with our Past report.

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of novel drugs to address unmet medical needs in China and internationally, with a market cap of HK$38.82 billion.

Operations: Kelun-Biotech generates revenue primarily from the pharmaceutical segment, which amounted to CN¥1.88 billion. The company focuses on novel drug development and commercialization to meet medical needs in China and globally.

Sichuan Kelun-Biotech Biopharmaceutical has demonstrated robust growth, with revenue increasing by 24.7% annually, outpacing the Hong Kong market's 7.3%. Despite being unprofitable, earnings are forecasted to grow at an annual rate of 8.53%, positioning the company for future profitability within three years. Significant investment in R&D is evident; the company allocated CNY 310 million in H1 2024 towards developing innovative treatments like sacituzumab tirumotecan (sac-TMT), which has shown promising results in clinical trials for various cancers.

• Take a closer look at Sichuan Kelun-Biotech Biopharmaceutical's potential here in our health report.

• Learn about Sichuan Kelun-Biotech Biopharmaceutical's historical performance.

Akeso (SEHK:9926)

Simply Wall St Growth Rating: ★★★★★★

Overview: Akeso, Inc. is a biopharmaceutical company that focuses on the research, development, manufacturing, and commercialization of antibody drugs with a market cap of approximately HK$50.22 billion.

Operations: Akeso generates revenue primarily from the research, development, production, and sale of biopharmaceutical products, amounting to CN¥1.87 billion. The company is involved in the entire lifecycle of antibody drugs from inception to market.

Akeso's revenue forecast of 32.9% growth per year indicates a promising trajectory, despite recent financial setbacks with a net loss of CNY 238.59 million in H1 2024. The company has been heavily investing in R&D, allocating substantial resources to develop innovative treatments like ivonescimab, which has shown significant clinical value and secured priority review for multiple indications. Earnings are projected to grow at an impressive rate of 54.67% annually, positioning Akeso for potential profitability within three years.

• Click here and access our complete health analysis report to understand the dynamics of Akeso.

• Evaluate Akeso's historical performance by accessing our past performance report.

Seize The Opportunity

• Unlock more gems! Our SEHK High Growth Tech and AI Stocks screener has unearthed 42 more companies for you to explore.Click here to unveil our expertly curated list of 45 SEHK High Growth Tech and AI Stocks.
• Are any of these part of your asset mix? Tap into the analytical power of Simply Wall St's portfolio to get a 360-degree view on how they're shaping up.
• Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Want To Explore Some Alternatives?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com